The Japanese patent authority, JPO has formally approved the company’s patent application of the antibody CAN04 (nidanilimab).
CAN04 binds interleukin 1 receptor accessory protein (IL1RAP), blocks its activity and the antibody is being developed for cancer therapy. The granted patent has number JP6396488.
The main project, the immuno-oncology antibody CAN04, with a dual mechanism of action, is currently investigated in a phase I/IIa clinical trial focused on treatment of non-small cell lung cancer and pancreatic cancer. The patent application which now has been granted in Japan concerns the product candidate CAN04, as well as its use in cancer treatment. Cantargia has already corresponding patent protection in e.g. Europe, USA and China. The patent in Japan confers protection until 2035. Cantargia also has granted patents around IL1RAP as a target molecule for antibody-based cancer therapy.
”Besides USA and Europe, Japan is the biggest market for pharmaceuticals. The granted patent is of high importance in a future commercialization of CAN04 on this strategically important market,” says Göran Forsberg, CEO of Cantargia in a press release.
